Final Update: Jan 1, 2023 | Companies listed: 32
| Company | Drugs, Targets, Platforms | Therapeutic Areas, Indications | Lead Phase |
|---|---|---|---|
| Coya Therapeutics, Inc. | Treg enhancing agents, allogeneic Treg-derived exosomes, autologous Treg cell therapy | FTD, ALS, neurodegenerative, autoimmune & metabolic diseases | Preclin |
| Lipella Pharmaceuticals Inc. | Intravesical liposomal tacrolimus | Hemorrhagic cystitis, Oral Lichen Planus, Intravesical MRI contrast agent | II |
| Cadrenal Therapeutics, Inc. | Vitamin K antagonist (anticoagulant) | End-stage renal disease, Atrial Fibrillation | III |
| Curative Biotechnology, Inc. | Oligodeoxynucleotide, Anti-CD56 ADC, metformin reformulation | Rabies, COVID-19, Glioblastoma, Age-related macular degeneration | I/II |
| Bullfrog AI Holdings, Inc. | Mebendazole formulation, siRNA targeting Beta2-spectrin | Glioblastoma, HCC, morbid obesity, NASH, NAFLD, CRC | I+ |
| Acrivon Therapeutics, Inc. | CHK1/CHK2, WEE1, PKMYT1 inhibitors | Cancer (Ovarian, Endometrial, Bladder, HPV+ SCC) | II |
| Clearmind Medicine Inc. | MEAI (5-Methoxy-2-aminoindane) | Alcohol Use Disorder, Binge Eating, Depression, TRD | Preclin |
| Intensity Therapeutics, Inc. | Cisplatin/Vinblastine combined with SHAO (amphiphilic cell penetration enhancer) | Oncology: STS, Breast, CRC, Bile Duct, Pancreatic, Squamous cell, Sarcoma, Hepatic, TNBC (neoadjuvant & metastatic) | III |
| Prime Medicine, Inc. | Ex-vivo, LNP, AAV delivered Prime Editing technology | SCD, Chronic Granulomatous Disease, Cystic Fibrosis, Wilson's Disease, GSD1b, Retinitis Pigmentosa, Usher Syndrome, GJB2 Hearing Loss, Friedreich's Ataxia, DM1, ALS, DMD, Oculopharyngeal muscular dystrophy, Fragile X Syndrome, Huntington's Disease | Disc |
| Jupiter Neurosciences, Inc. | Resveratrol in patented micellar preparation | Friedreich's Ataxia, Early Alzheimer's, MPS Type I, MELAS, ALS, Traumatic brain injury/concussion | II |
| Shuttle Pharmaceuticals | Radiation therapy sensitizers, HDAC inhibitors | Sarcoma, rectal cancer, proton therapy, pancreatic, BC | I+ |
| PaxMedica, Inc. | IV, intranasal formulations of suramin | Long COVID, Autism, Fragile X-Associated Tremor-Ataxia Syndrome (FXTAS) | IIb |
| bioAffinity Technologies, Inc. | Lung cancer diagnostic, siRNAs (CD320, LRP2) | Oncology | Disc |
| Ainos | Low dose oral IFN-a, RNA vaccine | Sjogren's Syndrome, Thrombocytopenia, COVID | III |
| MAIA Biotechnology | Telomere targeting agents | NSCLC, CRC, HCC, SCLC | II |
| Senti Bio | Off-the-shelf CAR-NK cells, gene therapy, cell therapies (regenerative medicine) | AML, HCC, CRC, CEA+ solid tumors, regenerative medicine | Preclin |
| Okyo Pharma | Chemerin peptide conjugate (CHEMR23/CMKLR1) | Dry Eye Disease, Non-infectious anterior uveitis, allergic conjunctivitis, ocular pain | IND |
| Intrinsic Medicine | Synthetic HMOs (human milk oligosaccharides) | IBS-constipation & diarrhea, rheumatoid & juvenile idiopathic arthritis, atopic dermatitis, autism | R&D |
| PepGen | Peptide-conjugated oligonucleotides, Exon 51, Exon 53, Exon 44, Exon 45, DMPK | DMD, DM1 | I |
| Hilllevax | Bivalent GI.1/GII.4 VLP-based vaccine | Norovirus-related illness | II |
| Belite Bio | RBP4-retinol, RBP4 | Dry AMD, Stargardt Disease, NASH, T2D | III |
| AN2 Therapeutics | Bacterial leucyl-tRNA synthetase (LeuRS) inhibitor | Chronic non-tuberculous mycobacterial (NTM) lung disease | Ib+ |
| Ocean Biomedical | Angiotensin 1-7, Anit-Chi311, Chit1 inhibitor, anti-PfGARP, PfGARP inhibitor, PfSEA-1 vaccine | NSCLC, GBM, pulmonary fibrosis (IPF, HPS), malaria, COVID-19 | I/II |
| Blue Water Vaccines, Inc. | Universal flu vaccine, H1 pre-pandemic vaccine, Intranasal S. pneumoniae vaccine, Norovirus, Rotavirus, Malaria | Prevention of infectious diseases | Preclin |
| TC BioPharm (Holdings) plc | Unmodified allogeneic gamma-delta T cells (CAR-T) | AML, COVID-19, solid/heme tumors | I+ |
| Nuvectis Pharma, Inc. | HSF1 inhibitor, SRC/YES1 kinase inhibitor, synthetic lethality | Ovarian CCC, Endometrioid ovarian, ARID1a mutated advanced solid tumors, SRC kinase/YES1 kinase-driven solid tumors | I |
| Arcellx, INC. | CAR-T (BCMA, CD123) | MM, AML/MDS, Solid tumors, SCLC, HCC | I |
| Samsara Vision, Inc. | "Implantable miniature telescope" medical device | AMD | Market |
| Hillstream Biopharma, INC. | Iron-mediated cell death (Ferroptosis) by salinomycin, PI3K-delta, HDAC6, TNF-alpha gene therapy | SCLC, solid tumors, sarcomas | I |
| Vigil Neuroscience, Inc. | Anti-TREM2 mAb, small molecule TREM2 agonist | Neurology, ALSP, cALD, Alzheimer's | I |
| CinCor Pharma, Inc. | Aldosterone synthase inhibitor | Uncontrolled Hypertension and high plasma aldosterone | II |
| Amylyx Pharmaceuticals, Inc. | Sodium phenylbutyrate/taurursodiol | ALS, Alzheimer's, Wolfram syndrome | NDA |